HER2-POSITIVE BREAST CANCER

This study tested whether two drugs, zanidatamab and evorpacept, are safe and can shrink tumors in people with advanced HER2-expressing cancers. Fifty-two patients with breast or other cancers that had spread or couldn't be removed by surgery took part. The goal was to see how ma…

This phase 2 trial tests a new drug called TVB-2640 (denifanstat) combined with trastuzumab and either chemotherapy (paclitaxel) or hormone therapy in 17 people with HER2+ metastatic breast cancer that no longer responds to trastuzumab. TVB-2640 blocks an enzyme cancer cells need…

This phase II trial tested a combination of two targeted antibodies (pertuzumab and trastuzumab) plus a chemotherapy drug (nab-paclitaxel) in 63 patients with HER2-positive advanced breast cancer. The goal was to see how well the drugs work together to stop tumor growth and impro…

This study tested whether taking oral chemotherapy pills (vinorelbine or capecitabine) along with the targeted drug trastuzumab can help prevent breast cancer from coming back in women with small, HER2-positive tumors that have not spread to lymph nodes. The 182 participants took…

This early-phase study tested a vaccine made from patients' own immune cells to target HER2-positive breast cancer. 31 participants with stage II or III breast cancer received the vaccine alongside standard chemotherapy before surgery. The goal was to see if the vaccine could boo…

This early-phase trial tested a combination of two drugs—copanlisib and trastuzumab—in 26 women with advanced HER2-positive breast cancer that had worsened after prior treatment. The goal was to find the safest dose and see if the combination could shrink tumors or slow disease p…

This early-phase trial tested an experimental drug called BAT8010 in 23 people with advanced or metastatic solid tumors who had no other standard treatment options. The main goals were to check safety, find the best dose, and see if the drug shows any sign of shrinking tumors. Pa…

This study tested a combination of two drugs, tucatinib and trastuzumab deruxtecan (T-DXd), in 70 people with advanced HER2-positive breast cancer that had spread or couldn't be removed by surgery. The goal was to see how well the drugs shrank tumors and what side effects occurre…

This study looked at how well the drug tucatinib (Tukysa) works in everyday medical practice for people with advanced HER2-positive breast cancer who had already tried at least two other treatments. Researchers tracked 49 adults in Germany and Austria to see how their quality of …

This Phase 3 trial tested whether replacing standard taxane chemotherapy (paclitaxel or docetaxel) with eribulin, when combined with pertuzumab and trastuzumab, could control advanced HER2-positive breast cancer just as well while causing less nerve damage. The study enrolled 446…

This study tests two new radioactive imaging agents, 99mTc-ADAPT6 and 99mTc-DARPinG3, to see how well they can detect HER2-positive breast cancer using SPECT scans. Fifteen women with HER2-positive breast cancer will receive injections of each agent a few days apart, followed by …

This study tested a special imaging tracer (99mTc-DARPinG3) to measure HER2 protein levels in breast cancer tumors using SPECT scans. Fifteen women with HER2-positive breast cancer received the tracer before and during chemotherapy plus targeted therapy. The goal was to see if th…

This pilot study tested a new radioactive tracer called 89Zr-DFO*-trastuzumab in 6 people with HER2-positive breast or gastric cancer. The tracer is designed to attach to HER2 proteins on cancer cells and show up on PET scans. Participants received one injection and had up to 4 P…

This study looked at whether women with early-stage breast cancer benefit from having a breast MRI in addition to standard mammograms before surgery. Researchers tracked 319 women to see if the MRI helped reduce the chance of cancer coming back, lowered the need for repeat surger…

This completed study from Semmelweis University looked at whether the breast cancer drug trastuzumab (Herceptin) causes dry eye or other eye surface problems. 35 adults with HER2-positive breast cancer took the drug as prescribed and visited the clinic every 3 months for eye exam…

This study looked at how well anti-HER2 drugs work in Egyptian women with HER2-positive breast cancer. Researchers followed 80 patients who received either one drug (trastuzumab) or a combination (trastuzumab plus pertuzumab or lapatinib) as part of their regular care. The goal w…

This completed study observed 22 adults with HER2-positive or HER2-low metastatic breast cancer who were taking trastuzumab deruxtecan (Enhertu) as part of routine care. Researchers tracked how many patients stopped treatment early or needed dose changes, and why. The goal is to …

This study reviewed medical records of 111 adults with early-stage HER2-positive breast cancer who received the drug neratinib after their initial treatment. The goal was to describe their age, gender, health conditions, and tumor details. This was an observational study, meaning…

This completed study looked at over 1,500 women with early-stage HER2-positive or triple-negative breast cancer who had no signs of cancer in their lymph nodes on ultrasound. All had breast-conserving surgery with lymph node removal. The goal was to see how often cancer actually …